| McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome K Legault, H Schunemann, C Hillis, C Yeung, EA Akl, M Carrier, ... Journal of Thrombosis and Haemostasis 16 (8), 1656-1664, 2018 | 125 | 2018 |
| McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome K Legault, H Schunemann, C Hillis, C Yeung, EA Akl, M Carrier, ... Arthritis Research and Therapy 19 (1), 287, 2017 | 125 | 2017 |
| Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery A Coppola, J Windyga, A Tufano, C Yeung, MND Di Minno Cochrane Database of Systematic Reviews, 2015 | 72 | 2015 |
| NHF‐McMaster guideline on care models for haemophilia management M Pai, NS Key, M Skinner, R Curtis, M Feinstein, C Kessler, SJ Lane, ... Haemophilia 22, 6-16, 2016 | 65 | 2016 |
| Strategies for eliciting and synthesizing evidence for guidelines in rare diseases M Pai, CHT Yeung, EA Akl, A Darzi, C Hillis, K Legault, JJ Meerpohl, ... BMC medical research methodology 19, 1-10, 2019 | 61 | 2019 |
| Care models in the management of haemophilia: a systematic review CHT Yeung, N Santesso, M Pai, C Kessler, NS Key, M Makris, ... Haemophilia 22, 31-40, 2016 | 42 | 2016 |
| Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing A Nagao, CHT Yeung, F Germini, T Suzuki Thrombosis Research 173, 79-84, 2019 | 39 | 2019 |
| Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models CHT Yeung, S Fong, PRV Malik, AN Edginton Maternal & child nutrition 16 (2), e12938, 2020 | 36 | 2020 |
| Impact of adopting population pharmacokinetics for tailoring prophylaxis in haemophilia A patients: a historically controlled observational study M Stemberger, F Kallenbach, E Schmit, A McEneny-King, F Germini, ... Thrombosis and haemostasis 119 (03), 368-376, 2019 | 32 | 2019 |
| A physiological approach to pharmacokinetics in chronic kidney disease PRV Malik, CHT Yeung, S Ismaeil, U Advani, S Djie, AN Edginton The Journal of Clinical Pharmacology 60, S52-S62, 2020 | 24 | 2020 |
| Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo … P Chelle, CHT Yeung, SE Croteau, J Lissick, V Balasa, C Ashburner, ... Clinical pharmacokinetics 59, 245-256, 2020 | 22 | 2020 |
| Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical … CHT Yeung, N Santesso, D Zeraatkar, A Wang, M Pai, M Sholzberg, ... Haemophilia 22, 41-50, 2016 | 19 | 2016 |
| Pharmacokinetic‐tailored approach to hemophilia prophylaxis: medical decision making and outcomes SE Croteau, AP Wheeler, O Khan, KM Haley, AJ Borst, S Lattimore, ... Research and Practice in Thrombosis and Haemostasis 4 (2), 326-333, 2020 | 16 | 2020 |
| Methodology for the development of the NHF‐McMaster Guideline on Care Models for Haemophilia Management M Pai, N Santesso, CHT Yeung, SJ Lane, HJ Schünemann, A Iorio Haemophilia 22, 17-22, 2016 | 15 | 2016 |
| Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients P Chelle, CHT Yeung, S Bonanad, JC Morales Muñoz, MC Ozelo, ... Journal of pharmacokinetics and pharmacodynamics 46, 427-438, 2019 | 14 | 2019 |
| Management of cardiovascular disease in aging persons with haemophilia REG Schutgens, M Voskuil, EP Mauser-Bunschoten Hämostaseologie 37 (03), 196-201, 2017 | 14 | 2017 |
| Clinical application of web accessible population pharmacokinetic service—hemophilia (WAPPS‐Hemo): patterns of blood sampling and patient characteristics among clinician users A McEneny‐King, CHT Yeung, AN Edginton, A Iorio, SE Croteau Haemophilia 26 (1), 56-63, 2020 | 11 | 2020 |
| A novel, enriched population pharmacokinetic model for recombinant factor VIII-Fc fusion protein concentrate in hemophilia A patients LH Bukkems, JM Heijdra, M Mathias, PW Collins, CRM Hay, RC Tait, ... Thrombosis and haemostasis 120 (05), 747-757, 2020 | 10 | 2020 |
| Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study SJ Lane, NS Sholapur, CHT Yeung, A Iorio, NM Heddle, M Sholzberg, ... Haemophilia 22, 23-30, 2016 | 10 | 2016 |
| Inhibitors in hemophilia A: a pharmacoeconomic perspective A Messori Seminars in Thrombosis and Hemostasis 44 (06), 561-567, 2018 | 9 | 2018 |
